Tags

Type your tag names separated by a space and hit enter

Inhibitors of cannabinoid receptors and glucose metabolism.
Curr Opin Clin Nutr Metab Care. 2008 Jul; 11(4):505-11.CO

Abstract

PURPOSE OF REVIEW

Abdominal obesity is closely related to type 2 diabetes and overactivity of the endocannabinoid system. The present review aims at evaluating the role of endocannabinoid system in glucose dysregulation and the effects of cannabinoid 1 receptor blockade on glucose metabolism in both animal models and overweight/obese humans, especially with type 2 diabetes.

RECENT FINDINGS

Cannabinoid 1 receptors have been identified not only in the brain, but also in the adipose tissue, the gut, the liver, the skeletal muscle and even the pancreas, all organs playing a key role in glucose metabolism and type 2 diabetes. Rimonabant, the first selective cannabinoid 1 receptor blocker in clinical use, has been shown to reduce body weight, waist circumference, glycated haemoglobin, triglycerides, insulin resistance index, and to increase HDL cholesterol and adiponectin concentrations in patients with type 2 diabetes, confirming data on nondiabetic overweight/obese patients. Almost half of the metabolic changes, including glycated haemoglobin reduction, could not be explained by weight loss, in agreement with direct peripheral effects.

SUMMARY

Cannabinoid 1 blockade reduces food intake and body weight and improves metabolic regulation beyond just weight loss. Because of its positive effect on glucose metabolism, rimonabant deserves consideration in the treatment of overweight/obese patients with type 2 diabetes.

Authors+Show Affiliations

Division of Diabetes, Nutrition and Metabolic Disorders, CHU Sart Tilman, University of Liège, Liège, Belgium. andre.scheen@chu.ulg.ac.beNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18542014

Citation

Scheen, André J., and Nicolas Paquot. "Inhibitors of Cannabinoid Receptors and Glucose Metabolism." Current Opinion in Clinical Nutrition and Metabolic Care, vol. 11, no. 4, 2008, pp. 505-11.
Scheen AJ, Paquot N. Inhibitors of cannabinoid receptors and glucose metabolism. Curr Opin Clin Nutr Metab Care. 2008;11(4):505-11.
Scheen, A. J., & Paquot, N. (2008). Inhibitors of cannabinoid receptors and glucose metabolism. Current Opinion in Clinical Nutrition and Metabolic Care, 11(4), 505-11. https://doi.org/10.1097/MCO.0b013e3282fcea11
Scheen AJ, Paquot N. Inhibitors of Cannabinoid Receptors and Glucose Metabolism. Curr Opin Clin Nutr Metab Care. 2008;11(4):505-11. PubMed PMID: 18542014.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibitors of cannabinoid receptors and glucose metabolism. AU - Scheen,André J, AU - Paquot,Nicolas, PY - 2008/6/11/pubmed PY - 2008/10/18/medline PY - 2008/6/11/entrez SP - 505 EP - 11 JF - Current opinion in clinical nutrition and metabolic care JO - Curr Opin Clin Nutr Metab Care VL - 11 IS - 4 N2 - PURPOSE OF REVIEW: Abdominal obesity is closely related to type 2 diabetes and overactivity of the endocannabinoid system. The present review aims at evaluating the role of endocannabinoid system in glucose dysregulation and the effects of cannabinoid 1 receptor blockade on glucose metabolism in both animal models and overweight/obese humans, especially with type 2 diabetes. RECENT FINDINGS: Cannabinoid 1 receptors have been identified not only in the brain, but also in the adipose tissue, the gut, the liver, the skeletal muscle and even the pancreas, all organs playing a key role in glucose metabolism and type 2 diabetes. Rimonabant, the first selective cannabinoid 1 receptor blocker in clinical use, has been shown to reduce body weight, waist circumference, glycated haemoglobin, triglycerides, insulin resistance index, and to increase HDL cholesterol and adiponectin concentrations in patients with type 2 diabetes, confirming data on nondiabetic overweight/obese patients. Almost half of the metabolic changes, including glycated haemoglobin reduction, could not be explained by weight loss, in agreement with direct peripheral effects. SUMMARY: Cannabinoid 1 blockade reduces food intake and body weight and improves metabolic regulation beyond just weight loss. Because of its positive effect on glucose metabolism, rimonabant deserves consideration in the treatment of overweight/obese patients with type 2 diabetes. SN - 1363-1950 UR - https://www.unboundmedicine.com/medline/citation/18542014/Inhibitors_of_cannabinoid_receptors_and_glucose_metabolism_ L2 - https://doi.org/10.1097/MCO.0b013e3282fcea11 DB - PRIME DP - Unbound Medicine ER -